消费者可穿戴设备用于评估心率控制使用狄戈辛与β阻塞剂:RATE-AF随机试验
Simrat K Gill1, Andrey Barsky2, Xin Guan2
1Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK.
Nature medicine
|July 15, 2024
概括
在心房的患者中,迪戈辛和β阻塞剂显示出相当的心率效应. 可穿戴技术有效监测患者,为心律失常管理提供了面对面评估的替代方案.
科学领域:
- 心脏病学 心脏病学
- 数字健康数字健康
- 临床试验 临床试验
背景情况:
- 消费者可穿戴设备为临床研究和患者管理提供了潜力.
- 永久性心房动和心力衰竭是老年人常见的并发症.
- 迪戈辛和β抑制剂是这些疾病的标准治疗方法,但它们对心率的比较影响需要进一步研究.
研究的目的:
- 在老年患者中,与永久性心房动和心力衰竭的老年患者中,比较狄戈辛与β抑制剂对心率的影响.
- 评估可穿戴技术在监测心率和身体活动方面的实用性.
- 评估可穿戴数据预测纽约心脏协会功能类的能力.
主要方法:
- 在RATE-AF试验的可穿戴设备研究中,有53名参与者 (平均年龄75.6岁) 患有永久性心房动和心力衰竭.
- 参与者被随机分配到迪戈辛或β-阻断剂治疗中,并使用手腕穿戴可穿戴设备监测了20周.
- 收集了心率和身体活动数据,并使用卷积神经网络来分析数据并预测功能类.
主要成果:
- 迪戈辛和β阻塞剂组之间没有观察到心率的显著差异,即使考虑到身体活动或高活动水平.
- 可穿戴设备数据预测了纽约心脏协会的功能类与标准临床测量 (F1评分0.55) 相似的准确性 (F1评分0.56).
- 数据表明,狄戈辛和β-阻断剂对静止状态和运动期间的心率具有同等影响.
结论:
- 在心房的患者中,迪戈辛和β阻塞剂对心率有相似的影响.
- 可穿戴技术为动态,远程监测心律失常患者提供了可行的替代方案,可能减少频繁的面对面评估的需要.
- 这项研究支持将可穿戴设备集成到临床实践中,用于管理心血管疾病.
更多相关视频
相关概念视频
01:30Pulse rhythm
782
Pulse rhythm refers to the pattern of pulsations within specific intervals, offering valuable insights into the regularity or irregularity of the heart's beats as observed through the pattern of pulsation within specific intervals. A regular pulse exhibits a consistent heart rate with uniform waveforms and pulsation force, variations of which can be classified as normal, weak, or bounding.
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac...
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac...
782
01:26Heart Failure Drugs: Inotropic Agents
564
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
564
01:22Heart Failure Drugs: β-Blockers
336
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
733
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
733
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
822
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
822
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
430
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
430